D. Boral Capital Reaffirms "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL)

Key Points

• D. Boral Capital reaffirmed a "Buy" rating on Anavex with a $24 price target, implying about a 480.97% upside from the company's current price.
• Analyst views are mixed—two Buys, one Hold and one Sell—resulting in an average consensus rating of "Hold" and an average price target of $22.
• Anavex is a clinical‑stage biopharma developing blarcamesine (ANAVEX2‑73) for Alzheimer's and Parkinson's dementia; shares recently opened at $4.13 with a market cap of ~$369.1 million and a 52‑week range of $2.86–$14.25.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They presently have a $24.00 target price on the biotechnology company's stock. D. Boral Capital's price objective indicates a potential upside of 480.97% from the company's current price.

A number of other equities analysts also recently weighed in on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Anavex Life Sciences in a research report on Monday, December 29th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of Anavex Life Sciences in a report on Friday, December 19th. Finally, Jones Trading lowered Anavex Life Sciences from a "buy" rating to a "hold" rating in a research report on Friday, October 24th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $22.00.

Anavex Life Sciences Stock Up 4.6%

Shares of NASDAQ AVXL opened at $4.13 on Tuesday. The firm has a market cap of $369.10 million, a P/E ratio of -7.68 and a beta of 1.17. Anavex Life Sciences has a 52 week low of $2.86 and a 52 week high of $14.25. The business's 50 day moving average price is $4.73 and its 200 day moving average price is $8.07.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last released its quarterly earnings data on Tuesday, November 25th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. During the same period in the previous year, the firm posted ($0.14) earnings per share. As a group, research analysts expect that Anavex Life Sciences will post -0.69 earnings per share for the current year.

Hedge Funds Weigh In On Anavex Life Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC lifted its holdings in shares of Anavex Life Sciences by 2.8% in the second quarter. Geode Capital Management LLC now owns 2,019,795 shares of the biotechnology company's stock valued at $18,624,000 after purchasing an additional 54,985 shares in the last quarter. Two Sigma Investments LP raised its position in shares of Anavex Life Sciences by 6.5% in the 3rd quarter. Two Sigma Investments LP now owns 1,036,954 shares of the biotechnology company's stock worth $9,229,000 after acquiring an additional 63,685 shares in the last quarter. Nwam LLC lifted its holdings in Anavex Life Sciences by 2.4% in the second quarter. Nwam LLC now owns 1,024,479 shares of the biotechnology company's stock valued at $9,446,000 after acquiring an additional 24,128 shares during the period. Invesco Ltd. lifted its holdings in shares of Anavex Life Sciences by 55.8% in the 2nd quarter. Invesco Ltd. now owns 863,959 shares of the biotechnology company's stock valued at $7,966,000 after acquiring an additional 309,605 shares during the last quarter. Finally, UBS Group AG raised its holdings in Anavex Life Sciences by 3.8% in the third quarter. UBS Group AG now owns 491,977 shares of the biotechnology company's stock worth $4,379,000 after purchasing an additional 17,823 shares in the last quarter. Institutional investors own 31.55% of the company's stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company's lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer's disease and Parkinson's disease dementia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.